Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and rheumatoid arthritis.
- stand: 03
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
- stand: 08
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
- stand: 01
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit our website.
Immuno-oncology is a top priority for Merck and Pfizer. The alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck. The alliance will jointly develop and commercialise avelumab and is striving to find new ways to treat cancer.
- stand: 06
Personal Genome Diagnostics
PGDx’s comprehensive genomic technologies empower the fight against cancer. PGDx is driving toward broad patient access to its genomic approaches, through a CLIA-certified facility providing comprehensive genomic services, as well as its PROGENEUS™ technology transfer solution and in vitro diagnostic products to enable other molecular laboratories to easily internalise testing.
- stand: 04
Bavarian Nordic is committed to building a pipeline of immunotherapy candidates targeting cancers with high unmet medical needs. In collaboration with the National Cancer Institute, BN has developed a portfolio designed to alter the disease course by eliciting robust and broad anti-cancer immune responses while maintaining favorable risk-benefit profiles. Through multiple industry collaborations, BN seeks potential synergies of combining our immunotherapies with other immune-modulating agents.
Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Whether you seek to target new biomarkers or to optimise the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you reach your next research breakthrough.
- stand: 07
Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives
- stand: 02